<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105860">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01869062</url>
  </required_header>
  <id_info>
    <org_study_id>ICSY01</org_study_id>
    <nct_id>NCT01869062</nct_id>
  </id_info>
  <brief_title>Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography</brief_title>
  <acronym>SonR-ECHO</acronym>
  <official_title>Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorin Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorin Group</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Portugal : Ethics Committee</authority>
    <authority>Canada: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the SONR-ECHO trial is to demonstrate that optimization of CRT
      parameters by SonR technology is able to increase the rate of CRT-D responders, based on
      significant LV reverse remodeling, as compared to Standard of Care settings.

      This study will also evaluate the effectiveness of CRT-D SonR system as compared to Standard
      of care (SoC) programming methods in providing appropriate LV filling, as expected from the
      Ritter method.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>CRT-responders rate increase based on LVESV decrease at M6 / baseline</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>A-wave truncation assessment at M6</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Report LV remodeling from LVEDV decrease at M6 / baseline</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">328</enrollment>
  <condition>Cardiac Resynchronization Therapy</condition>
  <arm_group>
    <arm_group_label>SonR optimization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SonR optimization algorithm ON</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SonR optimization on</intervention_name>
    <arm_group_label>SonR optimization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for implantation of a CRT-D device according to published relevant ESC and
             CCS guidelines ;

          -  In Sinus Rhythm;

          -  Have reviewed, signed and dated an informed consent

        Exclusion Criteria:

          -  Previous implant with a pacemaker, an Implantable Cardioverter-Defibrillator or a CRT
             device (except upgrade from single chamber ICD with a fully functional defibrillation
             lead  not under recall or surveillance);

          -  Persistent atrial arrhythmias (or cardioversion for Atrial Fibrillation)  within the
             past month;

          -  Ventricular tachyarrhythmia secondary to reversible causes such as acute myocardial
             infarction (MI), digitalis intoxication, drowning, electrocution, electrolyte
             imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment;

          -  Incessant ventricular tachyarrhythmia;

          -  Unstable angina, or acute MI, Coronary Artery Bypass-Grafting (CABG), or Percutaneous
             Transluminal Coronary Angioplasty (PTCA) within the past 4 weeks;

          -  Correctable valvular disease that is the primary cause of heart failure;

          -  Mechanical heart valve or indication for valve repair or replacement;

          -  Recent Cerebro-Vascular Accident (CVA) or Transient Ischemic Attack (TIA) (within the
             previous 3 months);

          -  Post heart transplant (patients who are waiting for a heart transplant are allowed in
             the study);

          -  Already included in another clinical study that could confound the results of this
             study;

          -  Life expectancy less than 1 year;

          -  Inability to understand the purpose of the study;

          -  Unavailability for scheduled follow-up or refusal to cooperate;

          -  Sensitivity to 1 mg Dexamethasone Sodium Phosphate (DSP);

          -  Age of less than 18 years;

          -  Pregnancy;

          -  Drug addiction or abuse;

          -  Under guardianship
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>François Philippon</last_name>
    <email>françois.philippon@med.ulaval.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut universitaire de Cardiologie et Pneumologie de Québec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François Philippon</last_name>
    </contact>
    <investigator>
      <last_name>François Philippon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>June 4, 2013</lastchanged_date>
  <firstreceived_date>May 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
